Acute myeloid leukemia

This study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…

This trial is testing whether a new conditioning regimen, called VABu, can improve outcomes for adults with acute myeloid leukemia (AML) who are in first remission but are too frail for standard transplant prep. The regimen combines venetoclax, azacitidine (or decitabine), and bu…

This trial tests whether a combination of sonrotoclax, cladribine, and cytarabine, followed by a stem cell transplant, can improve survival in adults with relapsed or refractory acute myeloid leukemia (AML). Participants receive the chemotherapy regimen, then undergo an allogenei…

This trial tests a combination of two drugs, azacitidine and venetoclax, as the first treatment for young, fit adults (ages 18-50) with newly diagnosed acute myeloid leukemia (AML). The goal is to see how many patients achieve complete remission after one or two cycles of this th…

This early-phase trial tests whether adding arsenic trioxide to a standard stem cell transplant can prevent the cancer from coming back in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls about 20 patients whose cancers have …

This phase 3 trial compares two drug combinations for adults with a high-risk form of myelodysplastic syndrome (MDS-IB2) or newly diagnosed acute myeloid leukemia (AML) that is either secondary to prior treatment or occurs in older age. One group receives a standard regimen of az…

This trial is testing whether adding venetoclax to standard intensive chemotherapy plus midostaurin can improve outcomes for adults with a type of acute myeloid leukemia that has a FLT3 mutation. The study enrolls people aged 18 to 70 with newly diagnosed disease who are healthy …

Researchers are testing a three-drug regimen called VAM for older or unfit adults with newly diagnosed acute myeloid leukemia (AML). The regimen combines liposomal mitoxantrone, azacitidine, and venetoclax. The trial aims to find the safest and most tolerable dose of liposomal mi…

This early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…

This study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part…

Researchers are testing whether adding hydroxychloroquine to oral decitabine and venetoclax helps adults with acute myeloid leukemia (AML) that has relapsed or stopped responding to similar treatment. The study enrolls about 18 people with relapsed or refractory AML, or newly dia…

This study tests a new combination of three drugs—revumenib, azacitidine, and venetoclax—in people newly diagnosed with a specific, hard-to-treat leukemia called KMT2A-rearranged AML. The goal is to see if this cocktail can help more patients achieve remission with fewer side eff…

This phase II trial tests whether adding venetoclax to standard chemotherapy and stem cell transplant, followed by venetoclax maintenance, helps adults with acute myeloid leukemia (AML) stay in remission longer. About 244 participants will receive either venetoclax or a placebo a…

This phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…

Researchers are testing an experimental drug called ORM-1153 in adults whose acute myeloid leukemia (AML) or other blood cancer has returned or stopped responding to treatment. The drug targets CD123, a protein found on the surface of these cancer cells. Participants receive ORM-…

This trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…

This phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CL…

This trial is testing whether adding the drug venetoclax to different chemotherapy regimens can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It compares three experimental combinations against the standard treatment in 320 patients aged 14 and ol…

This early-phase trial tests a new type of cell therapy for people with relapsed or refractory acute myeloid leukemia (AML). The treatment uses a patient's own immune cells, engineered to recognize six different targets on leukemia cells. The study aims to see if this approach is…

This study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…

This study tests an oral chemotherapy drug, cladribine, combined with two other drugs (low-dose cytarabine and venetoclax) in people with acute myeloid leukemia (AML). The first part finds the safest dose; the second part checks if that dose helps control the disease. About 58 ad…

This early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…

This early-stage trial is testing an experimental drug called monzosertib in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or not responded to standard treatment. The main goal is to find a safe and recommended dose of monz…

This early-phase study tests a new drug called PLM-102 in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to find the highest safe dose and to monitor side effects. Participants must have relapsed or refractor…

This trial is investigating whether a new drug called sonrotoclax, when combined with other anti-cancer medicines, is safe and effective for children and adolescents with acute myeloid leukemia (AML) or B-cell acute lymphoblastic leukemia (ALL) that has returned or not responded …

This trial is testing whether adding hydroxyurea to a standard chemotherapy combination can improve outcomes for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The study is conducted in two parts: first to find the safest dose of hydroxy…

This phase 3 trial is testing whether adding an umbilical cord blood infusion to standard consolidation chemotherapy can help older adults with intermediate- or high-risk acute myeloid leukemia (AML) stay free of relapse. About 132 patients aged 60 to 80 who achieved remission af…

This trial tests whether an experimental cell therapy called agenT-797 is safe for people receiving a stem cell transplant for blood cancers like leukemia or myelodysplastic syndrome. Participants get an infusion of agenT-797 about a week after their transplant. The main goal is …

This trial tests whether adding gilteritinib to the standard drugs azacitidine and venetoclax can help adults with a type of acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. Participants receive the three-drug combination in repeated 28-day…

This early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…

This phase 2 trial tests whether using a comprehensive geriatric assessment to guide treatment selection can reduce side effects and improve outcomes in adults aged 60 and older with newly diagnosed acute myeloid leukemia. Participants are classified as fit, vulnerable, or frail,…

This trial tests whether adding an experimental drug called CLN 049 to two standard AML drugs (azacitidine and venetoclax) is safe and tolerable for adults newly diagnosed with acute myeloid leukemia who are not candidates for intensive chemotherapy. The study will first find the…

This early-phase trial is testing an experimental drug called S241656, taken as a tablet, in people with relapsed or refractory acute myeloid leukemia (AML) and related blood cancers. The study aims to find a safe dose and see how the drug behaves in the body, both alone and when…

This trial tests whether adding the drug revumenib to standard chemotherapy (fludarabine and cytarabine) can help children and young adults with a rare form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The study enrolls up to 27 participants a…

This phase 2 trial tests whether a once-weekly oral combination of decitabine-cedazuridine and venetoclax is safer and as effective as standard therapy for people with relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, or high-risk myeloproliferati…

This early-phase trial tests a new approach using donor immune cells that have been mobilized through exercise to prevent or treat leukemia relapse after a stem cell transplant. The study will enroll 94 people with various blood cancers. Some will receive the exercise-mobilized c…

This early-phase trial tests a single injection of PID23, a gene therapy that instructs a patient's own immune cells to attack leukemia cells. It targets three markers (CD19, BCMA, and CD70) on cancer cells. The study enrolls up to 18 people aged 3 to 75 with relapsed or refracto…

This study aims to develop an artificial intelligence tool that helps doctors choose the right dose of cyclosporine for patients who have received a bone marrow transplant. Cyclosporine is used to prevent graft-versus-host disease, a serious complication where donor cells attack …

This trial tests whether a combination of two drugs, lisaftoclax and azacitidine, can help prevent acute myeloid leukemia (AML) from coming back in patients who have already received a stem cell transplant and are at high risk of relapse. Participants are randomly assigned to rec…

This trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…

This study tests whether taking a daily antibiotic (levofloxacin) can safely reduce infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. The trial will randomly assign 75 participants to either lev…

This study tests whether giving personalized maintenance therapy after a stem cell transplant can prevent cancer from coming back in people with certain blood cancers. About 450 adults with myeloid cancers who have signs of disease before transplant will be assigned to treatment …

This study compares a new drug combination (venetoclax plus azacitidine) against standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has NPM1 or IDH mutations. About 148 people will be randomly assigned to one of the two treatments. The main…

This study tests a new oral drug called revumenib in people with acute myeloid leukemia (AML) who have certain genetic changes. After a stem cell transplant, participants will take revumenib or a placebo to see if it helps keep the cancer from coming back. The trial involves 144 …

This study tests a new combination of drugs (chidamide, venetoclax, azacitidine, and homoharringtonine) as a first treatment for adults aged 18-60 with intermediate- to high-risk acute myeloid leukemia (AML). The goal is to see if this mix can improve remission rates and reduce t…

This trial is testing a combination of three chemotherapy drugs—clofarabine, busulfan, and melphalan—given before a stem cell transplant in 30 adults with acute myeloid leukemia (AML) who are in first remission. The goal is to see if this conditioning regimen improves survival an…

This study tests whether a two-week course of the VA-CAG chemotherapy works as well as the usual three-week course for adults newly diagnosed with acute myeloid leukemia (AML). About 110 participants will be randomly assigned to one of the two schedules. The goal is to see if the…

This phase 2 trial tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes. About 180 participants aged 15-60 will be randomly…

This trial tests a new automated radiation method that precisely targets bone marrow and lymph nodes before a stem cell transplant. The goal is to kill cancer cells while reducing damage to healthy tissues. Participants have high-risk myeloid cancers like acute myeloid leukemia o…

This trial investigates whether adding selinisole to standard chemotherapy drugs (azacitidine and venetoclax) can improve outcomes for people with newly diagnosed, high-risk myeloid tumors that have a TP53 mutation. These tumors are aggressive and hard to treat. The study will me…

This study is testing whether a two-drug combination (venetoclax and azacitidine) followed by a stem cell transplant can help people with a rare, hard-to-treat form of acute myeloid leukemia (AML). The trial will enroll 50 adults who have not been treated before. The goal is to s…

This early-phase study tests a new drug (ATRN-119) combined with a standard chemotherapy (decitabine) in 27 adults with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a TP53 gene change. The main goals are to find a safe dose and see if the combo can shrink…

This early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…

This study tests a reduced-intensity chemotherapy combination (fludarabine and treosulfan) before a half-matched stem cell transplant in 77 older or frail adults with AML. The goal is to see if this gentler regimen can control the leukemia long-term while being safe enough for pa…

This early-phase trial is testing a new personalized therapy called BSB-2002 for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses a patient's own immune cells (T cells) that are genetically modified to …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This study looks at a stem cell transplant from a half-matched donor (haploidentical) combined with drugs to prevent the cancer from coming back. It includes 40 adults aged 18-65 with active AML that has returned or not responded to treatment. The goal is to see if this approach …

This study tests whether a combination of three chemotherapy drugs (thiotepa, busulfan, and fludarabine) given before a stem cell transplant can help older adults with acute myeloid leukemia stay in remission longer. About 93 patients aged 55 to 75 who are in their first remissio…

This study tests whether adding SHR2554 and azacitidine to standard chemotherapy before a stem cell transplant can lower the chance of cancer returning in people aged 15-60 with high-risk or relapsed leukemia or myelodysplastic syndromes. Half the participants will get the new dr…

This study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back. About 28 participants will rec…

This early-phase study tests a new type of CAR-T cell therapy (FO33 CAR-T) for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target a protein called CD33 found on mos…

This Phase 3 trial tests whether adding venetoclax to azacitidine as maintenance therapy helps adults with acute myeloid leukemia (AML) stay in remission longer. About 788 patients who achieved first remission after initial treatment will receive either azacitidine alone or azaci…

This Phase 3 trial will test whether adding homoharringtonine to the standard two-drug regimen of venetoclax and azacitidine improves remission rates in adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). About 308 participants will be randomly assigned to receiv…

This Phase 2 trial tests whether adding other drugs to standard chemotherapy can eliminate leftover leukemia cells in adults aged 18-59 before a stem cell transplant. Participants who still have detectable disease after initial treatment will receive one of four drug combinations…

This study tests whether a combination of three drugs (chidamide, venetoclax, and azacitidine) can help prevent acute myeloid leukemia (AML) from coming back in patients who have already achieved remission. About 104 adults aged 18 to 80 will receive up to 12 cycles of treatment.…

This early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if t…

This early-phase trial is testing a new drug called axatilimab added to two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The study aims to find the safest dose of axatilimab and see how …

This study tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor (G-CSF) in 61 older or frail adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate standard intensive chemotherapy. The goal is to see if thi…

This phase 2 trial tests a new combination of drugs—lisafotoclax, decitabine, and homoharringtonine—in 35 adults with acute myeloid leukemia (AML) whose cancer did not respond to or could not tolerate the standard venetoclax/azacitidine regimen. The goal is to see if this new mix…

This study tests whether a three-drug combination (venetoclax, azacitidine, and gilteritinib) followed by strong chemotherapy works better than standard chemotherapy plus gilteritinib for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 …

This Phase 3 trial tests a new combination of drugs (venetoclax, azacitidine, and a liposomal form of mitoxantrone) against the standard therapy for adults newly diagnosed with acute myeloid leukemia (AML). The study will enroll 204 people aged 18-65 to see if the new combo leads…

This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—in people with acute myeloid leukemia (AML) who are either newly diagnosed and unable to tolerate standard chemotherapy, or whose cancer has returned or not responded to treatment. The trial ha…

This study compares a single antibiotic (amoxicillin-clavulanate) against the standard two-drug combination (amoxicillin-clavulanate plus ciprofloxacin) for treating fever caused by chemotherapy in adults with certain blood cancers. The goal is to see if the simpler treatment wor…

This study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from coming back in people over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills d…

This trial tests a new way to do cord blood transplants for young adults (ages 16-55) with very poor risk acute myeloid leukemia (AML). Participants get a standard cord blood transplant plus daily infusions of white blood cells called granulocytes for 1 to 7 days. The goal is to …

This study tests whether the drug interferon-α can lower the chance of cancer returning in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a TP53 gene mutation. Participants must have had a stem cell transplant and show no signs of cancer two m…

This early-stage study tests a new drug, CT1390B, in 18 adults whose acute myeloid leukemia has come back or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink or clear the cancer. Participants must be bet…

This study tests a special way to process donated stem cells to make transplants safer for people with leukemia or lymphoma. The goal is to reduce serious complications like graft-versus-host disease, where donor cells attack the patient's body. About 100 participants will receiv…

This study tests a new three-drug combination (gilteritinib, azacitidine, and venetoclax) against standard chemotherapy for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-ITD). About 230 newly diagnosed patients aged 18-75 who are healthy enough for intens…

This early-stage study tests a new type of CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses donor cells engineered to target a protein called CLL1 found on most AML cells, and is designed …

This study tests a combination of three drugs (cladribine, low dose cytarabine, and venetoclax) in 24 adults with acute myeloid leukemia (AML) that has relapsed or not responded to prior treatment, especially after a venetoclax-based regimen. The goal is to see if this combinatio…

This early-phase trial tests adding tocilizumab, a drug used for arthritis, to standard chemotherapy (azacitidine and venetoclax) for adults with acute myeloid leukemia (AML) who cannot have intensive treatment. The main goal is to find a safe dose and check for side effects. Onl…

This study tests whether giving a shorter course of the drug venetoclax (combined with azacitidine) works as well as the standard longer course for older or frail patients with acute myeloid leukemia (AML). The researchers will check bone marrow on day 14 to decide if the drug ca…

This study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…

This early-phase study tests a new type of CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to better find and attack leukemia cells. The main goal i…

This early-phase study tests two oral drugs, ziftomenib and mezigdomide, given together to adolescents and adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial focuses on people whose leukemia has specific genetic changes (KMT2A rea…

This early-phase study tests whether adding an experimental drug (VIC-1911) to standard medications can prevent graft-versus-host disease (GVHD) in children aged 8-18 who receive a stem cell transplant from a half-matched donor. GVHD occurs when donor cells attack the child's bod…

This study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive CLL1 CAR-T cells (engineered immune cells that target leukemia). Then they get a stem cell transplant from a donor. Th…

This early study tests a new treatment using the body's own immune cells, called CAR-T cells, to fight certain blood cancers (like T-cell leukemia/lymphoma) that have returned or not responded to standard therapy. The study will enroll about 20 to 28 adults aged 18-85. The main g…

This early-phase trial tests a new type of cell therapy called CAR-ITNK cells, designed to target two proteins (CD70 and CLL1) on leukemia cells. It will enroll 30 adults with relapsed or refractory acute myeloid leukemia (AML) who have not responded to standard treatments. Parti…

This study compares two ways of giving donor immune cells (DLI) after a stem cell transplant to prevent cancer from coming back in people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. One approach gives the cells early as a preventive measure…

This study tests whether combining two oral drugs, sorafenib and venetoclax, can eliminate leftover leukemia cells in people with acute myeloid leukemia (AML) who still have measurable residual disease (MRD) after initial treatment. About 87 participants will receive the drugs fo…

This early-stage trial tests a new treatment called CT0991, which uses a patient's own immune cells engineered to attack leukemia cells. It will enroll 24 adults with acute myeloid leukemia that has returned or not responded to standard therapy. The main goals are to check safety…

This study tests a new treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially modified immune cells from a healthy donor to attack the cancer. The first part finds the safest dose, and the second part checks how well i…

This phase 2 trial tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will enroll 27 adults aged 18 to 75. The main goal is…

This early-phase trial tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. First, patients receive special immune cells (CAR-T cells) that target two markers on leukemia cells, followed by a second type …

This study tests whether infusing umbilical cord blood can safely help elderly patients (ages 60-80) with MDS or AML recover from bone marrow suppression caused by chemotherapy. The treatment aims to improve blood cell counts and reduce complications like bleeding and infection. …

This study tests a new treatment called CCTx-001 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. CCTx-001 is a type of immunotherapy that uses a patient's own immune cells, modified to target a protein called IL-1RAP found …

This study tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML) who have active disease. Before a stem cell transplant, patients receive a radioactive antibody (131I-apamistamab) along with chemotherapy and low-dose radiation to prepare the bod…

Doctors often wait days for genetic tests to classify acute myeloid leukaemia (AML) and guide treatment. This trial tests whether breath analysis can detect metabolic products from leukaemia and classify the disease faster. Participants give breath samples and extra blood tests d…

This study tests a new blood test (5hmC) to see if it can help doctors choose between two standard treatments for acute myeloid leukemia (AML): a milder drug (hypomethylating agent) or strong chemotherapy. About 112 newly diagnosed adults will have their blood tested after initia…

This study looks at 60 people with acute myeloid leukemia to see if a computer method (FlowSOM) can detect leftover cancer cells as well as expert analysis. Researchers will compare results from both methods using stored blood samples. If the computer approach works, it could mak…

Researchers are testing whether removing a specific type of immune cell, called CD45RA-positive naive T cells, from donor stem cells can prevent graft-versus-host disease in older adults undergoing stem cell transplants for acute leukemia or myelodysplastic syndrome. The trial en…

Researchers are studying whether aloe vera mouthwash can prevent or reduce the severity of oral mucositis, a painful mouth sore that often affects people receiving chemotherapy for acute leukemia. The trial compares aloe vera mouthwash plus usual care against usual care alone in …

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This trial tests a method called Active Default to improve supportive care for adults 60 and older starting venetoclax-based therapy for acute myeloid leukemia (AML). Participants complete a geriatric assessment covering mobility, nutrition, mood, memory, and medications. If the …

This study compares hypnosis, virtual reality, and standard care to see which best reduces anxiety in adults starting chemotherapy for acute myeloid leukemia. About 99 patients will be randomly assigned to one of three groups. The goal is to find a non-drug way to help patients c…

Researchers at Assiut University Hospitals are studying whether three blood measures predict survival in adults newly diagnosed with non-M3 acute myeloid leukemia. The measures are the ratio of C-reactive protein to albumin, the ratio of albumin to fibrinogen, and the level of fe…

This study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …

This study explores whether patients with acute myeloid leukemia can receive intravenous cytarabine chemotherapy at home instead of in the hospital. Researchers will track how many patients complete the planned home treatment, how often doses are given at home versus the hospital…

This study looks at whether a blood test that detects tumor DNA (ctDNA) can give the same information as bone marrow tests in children with acute leukemia. Researchers will compare ctDNA results with standard bone marrow checks for minimal residual disease. The goal is to see if …

This study explores whether a non-invasive, painless skin measurement called electrical bioimpedance can help monitor acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). About 25 adults who are already scheduled for a bone marrow biopsy will also receive this skin te…

This study investigates how to engineer T cells to more effectively target acute myeloid leukemia (AML). Researchers will analyze samples from healthy donors and AML patients to identify T-cell receptors that recognize leukemia cells. The goal is to create next-generation enginee…

This pilot study tests whether adults aged 65 and older with acute leukemia can use a digital platform to complete health questionnaires from home. Twenty participants will fill out surveys about their quality of life and symptoms on a tablet or phone, with results sent directly …

This study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatment…

This study will collect blood and bone marrow samples from 55 adults with acute leukemia or myelodysplastic syndrome. Researchers want to understand how natural killer (NK) cells interact with cancer cells over time. The goal is to identify genetic markers and immune patterns tha…

This study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal …

This study is testing a new blood test called AlloHeme that looks for tiny traces of a patient's own cells after a stem cell transplant. The goal is to see if the test can predict whether leukemia or MDS will come back before it happens. About 400 adults who have had or will have…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …

This study will create a structured follow-up program for 400 children and young adults who have survived blood cancers like leukemia and lymphoma. Researchers want to better track and understand long-term health problems that can appear years after treatment. The goal is to impr…

This study will follow 80 adults with newly diagnosed acute myeloid leukemia (AML) who are receiving intensive chemotherapy. The goal is to measure changes in blood clotting profiles before and after treatment. Researchers hope to better understand bleeding risks and improve care…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…

This study follows up to 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track side effects, overall survival, and how long any response lasts. The goal …

This study will gather and combine medical and genetic data from 2,000 children with acute myeloid leukemia (AML) across France. The goal is to find hidden patterns that predict which patients are most likely to relapse. By creating a large, shared database, researchers hope to i…